08:05 AM EDT, 09/15/2025 (MT Newswires) -- aTyr Pharma ( ATYR ) reported Monday that a phase 3 study of efzofitimod to treat pulmonary sarcoidosis, a type of lung disease, missed its primary endpoint.

The study's primary endpoint was the change from baseline in mean daily oral corticosteroid dose at week 48.

The biotech company said it will seek a review of the results with the US Food and Drug Administration to "determine the path forward for efzofitimod in pulmonary sarcoidosis."

Shares of aTyr Pharma ( ATYR ) fell 5.8% in recent premarket activity.